Download this assay page in pdf format.
Specimen Type: Heparin Plasma
Optimum Volume: 0.5 mL
|8 days||1 year||1 year|
Reporting units: pmol/L
Biological or Clinical Significance:
MPO is an enzyme that is synthesized and stored within polymorphonuclear leukocytes (PMN’s) and monocytes. MPO generates an array of reactive oxidants and free radical species as part of its role in host defenses. These same reactive species can inflict oxidative damage on biological targets that, perhaps, include lipids and proteins, including components of HDL, which may be the major reason why increased MPO level has been shown to be an independent predictor of endothelial dysfunction, angiographically evident CAD, and incident cardiac risks in subjects. In addition, MPO and many of its oxidation products are enriched within human atherosclerotic plaque. Monocytes appear to release MPO, which catalyzes low-density lipoprotein oxidation within the vessel wall, rendering it in an atherogenic form recognized by macrophage scavenger receptors. MPO may also contribute to the atherosclerotic process by promoting endothelial dysfunction by virtue of its ability to catalytically consume nitric oxide.
Principle of Test Method:
The MPO assay is a solid-phase ELISA that employs the quantitative sandwich enzyme immunoassay principle.
1. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: An inflammatory enzyme for generating dysfunctional high density lipoprotein. Corr Opin Cardiol. 2006; 21:322-328.
2. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, and Hamm CW. Meyloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108: 1440-1445.
3. Prognostix, Inc. 510(k) Substantial Equivalence Determination-Decision Summary for CardioMPO, http://www.accessdata.fda.gov/cdrh_docs/reviews/K050029.pdf pg. 7.